International Clinical Trial: A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)

Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07213882) titled 'A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)' on Oct. 2.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Assistance Publique - Hopitaux de Paris

Condition: Cutaneous T Cell Lymphoma (CTCL) Mycosis Fungoides Sezary Syndrome

Intervention: Drug: DT-7012

Recruitment Status: Not recruiting

Phase: Early ...